Literature DB >> 21700031

Cefquinome sulfate behavior after intramammary administration in healthy and infected cows.

A Zonca1, M Gallo, C Locatelli, S Carli, P Moroni, R Villa, P Cagnardi.   

Abstract

Maintenance of adequate drug concentration at the site of infection is an important problem in mastitis antibiotic therapy, and the efficacy of intramammary β-lactams can be optimized by maintaining the drug concentration at the site of infection above the minimum inhibitory concentration (MIC) as long as possible. The most important pharmacokinetic and pharmacodynamic parameter for efficacy evaluation is time during which drug concentrations exceed the MIC (t>MIC). In this study, we assessed the pharmacokinetic profile of cefquinome (CFQ) after repeated intramammary administration in healthy cows and cows subclinically infected with Staphylococcus aureus as well as the MIC of Staph. aureus field strains. In addition, the degree of drug passage was investigated from udder to bloodstream by measuring systemic drug absorption in healthy and infected animals. Cefquinome concentrations were quantified by HPLC (UV-visible detection) in milk samples collected from quarters and from blood serum samples. The systemic drug absorption was negligible in healthy and subclinically infected animals (maximum concentration 0.09±0.02 and 0.1±0.01 μg/mL in healthy and subclinically infected animals, respectively). The MIC(90) value for CFQ in Staph. aureus field strains (n=20) was 0.24 μg/mL. The pharmacokinetic and pharmacodynamic evaluation, determined by t>MIC, showed an equal persistence of CFQ in all quarters, indicating an equivalent activity of the drug regardless of the pathological status of the udder. Moreover, with literature data regarding CFQ MIC, the t>MIC has been calculated for other bacterial species.
Copyright © 2011 American Dairy Science Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700031     DOI: 10.3168/jds.2010-4109

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  10 in total

1.  Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle.

Authors:  Ijaz Ahmad; Haihong Hao; Lingli Huang; Pascal Sanders; Xu Wang; Dongmei Chen; Yanfei Tao; Shuyu Xie; Kuang Xiuhua; Juan Li; Wan Dan; Zonghui Yuan
Journal:  Front Microbiol       Date:  2015-06-17       Impact factor: 5.640

2.  Development and validation of a UPLC-MS/MS method to monitor cephapirin excretion in dairy cows following intramammary infusion.

Authors:  Partha Ray; Katharine F Knowlton; Chao Shang; Kang Xia
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

3.  Dose Assessment of Cefquinome by Pharmacokinetic/Pharmacodynamic Modeling in Mouse Model of Staphylococcus aureus Mastitis.

Authors:  Yang Yu; Yu-Feng Zhou; Xiao Li; Mei-Ren Chen; Gui-Lin Qiao; Jian Sun; Xiao-Ping Liao; Ya-Hong Liu
Journal:  Front Microbiol       Date:  2016-10-07       Impact factor: 5.640

4.  Elimination kinetics of ceftiofur hydrochloride in milk after an 8-day extended intramammary administration in healthy and infected cows.

Authors:  Rongwei Han; Songli Li; Jun Wang; Zhongna Yu; Jiaqi Wang; Nan Zheng
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

5.  Efficacy of Cefquinome against Escherichia coli Environmental Mastitis Assessed by Pharmacokinetic and Pharmacodynamic Integration in Lactating Mouse Model.

Authors:  Yang Yu; Jin-Tao Fang; Jian Sun; Mei Zheng; Qing Zhang; Jie-Shun He; Xiao-Ping Liao; Ya-Hong Liu
Journal:  Front Microbiol       Date:  2017-08-02       Impact factor: 5.640

6.  Ex Vivo Pharmacokinetics and Pharmacodynamics Modeling and Optimal Regimens Evaluation of Cefquinome Against Bovine Mastitis Caused by Staphylococcus aureus.

Authors:  Li-Jie Jiang; Xia Xiao; Ke-Xu Yan; Tian Deng; Zhi-Qiang Wang
Journal:  Front Vet Sci       Date:  2022-03-08

7.  Intramammary treatment using allogeneic pure platelet-rich plasma in cows with subclinical mastitis caused by Gram-positive bacteria.

Authors:  Paulo C Duque-Madrid; Juan Velasco-Bolaños; Alejandro Ceballos-Márquez; Catalina López; Jorge U Carmona
Journal:  Sci Rep       Date:  2021-12-09       Impact factor: 4.379

8.  Preparation of cefquinome sulfate proliposome and its pharmacokinetics in rabbit.

Authors:  Qiang Fu; Hua-Lin Fu; Luo Huan; Wei Zhang; Guang Shu; Meng-Jiao Liu; Feng-Ying Deng; Jun Hu
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

9.  In Vivo Pharmacokinetics/Pharmacodynamics of Cefquinome in an Experimental Mouse Model of Staphylococcus Aureus Mastitis following Intramammary Infusion.

Authors:  Yang Yu; Yu-Feng Zhou; Mei-Ren Chen; Xiao Li; Gui-Lin Qiao; Jian Sun; Xiao-Ping Liao; Ya-Hong Liu
Journal:  PLoS One       Date:  2016-05-24       Impact factor: 3.240

10.  In vitro susceptibility of four antimicrobials against Riemerella anatipestifer isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin.

Authors:  Yafei Li; Yanan Zhang; Huanzhong Ding; Xian Mei; Wei Liu; Jiaxiong Zeng; Zhenling Zeng
Journal:  BMC Vet Res       Date:  2016-11-09       Impact factor: 2.741

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.